Pemetrexed therapy for malignant pleural mesothelioma

被引：2

作者：

Puto, K

Garey, JS

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Div Pharma, Houston, TX 77030 USA

[2] Jackson Mem Hosp, Dept Pharm, Miami, FL 33136 USA

来源：

ANNALS OF PHARMACOTHERAPY | 2005年 / 39卷 / 04期

关键词：

malignant pleural mesothelioma; pemetrexed;

D O I：

10.1345/aph.1E329

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

OBJECTIVE: To review pemetrexed, a novel multi-targeted antifolate agent. DATA SOURCES: A literature search was conducted (1985-September 2004) using MEDLINE and CANCERLIT Recent abstracts from the American Society of Clinical Oncology were also included, along with the manufacturer's information. Key words were pemetrexed, LY 231514, Alimta, multi-targeted antifolate, malignant pleural mesothelioma. STUDY SELECTION AND DATA EXTRACTION: Relevant information on pharmacology, pharmacokinetics, and safety and efficacy of pemetrexed from clinical trials was selected. DATA SYNTHESIS: Pemetrexed inhibits folate metabolism and purine/pyrimidine synthesis. Based on Phase I and II trials, pemetrexed has antitumor activity in solid tumors such as lung, colorectal, and cervical. A pivotal Phase III study in patients with malignant pleural mesothelioma (MPM) demonstrated survival superiority of pemetrexed-cisplatin regimen versus cisplatin. CONCLUSIONS: Pemetrexed is a promising new drug for the treatment of solid malignancies, most notably MPM.

引用

页码：678 / 683

页数：6

共 29 条

[1] Pemetrexed (ALIMTA), a novel multitargeted antineoplastic agent [J].

Adjei, AA .

CLINICAL CANCER RESEARCH, 2004, 10 (12) :4276S-4280S

[2] Phase I and pharmacologic study of sequences of gemcitabine and the multitargeted antifolate agent in patients with advanced solid tumors [J].

Adjei, AA ;

Erlichman, C ;

Sloan, JA ;

Reid, JM ;

Pitot, HC ;

Goldberg, RM ;

Peethambaram, P ;

Atherton, P ;

Hanson, LJ ;

Alberts, SR ;

Jett, J .

JOURNAL OF CLINICAL ONCOLOGY, 2000, 18 (08) :1748-1757

[3]

Adjei Alex A, 2004, Clin Lung Cancer, V5 Suppl 2, pS51

[4]

Adjei Alex A, 2003, Expert Rev Anticancer Ther, V3, P145, DOI 10.1586/14737140.3.2.145

[5]

CALVERT H, 2002, SEMIN ONCOL S5, V2, pS54

[6]

Carbone Michele, 2004, Clin Lung Cancer, V5 Suppl 2, pS46, DOI 10.3816/CLC.2004.s.002

[7] Pemetrexed disodium, a novel antifolate with multiple targets [J].

Curtin, N. J. ;

Hughes, A. N. .

LANCET ONCOLOGY, 2001, 2 (05) :298-306

[8]

*EL LILL, 2004, PACK INS AL PEM

[9]

Gadgeel Shirish M, 2004, Clin Lung Cancer, V5 Suppl 2, pS61, DOI 10.3816/CLC.2004.s.005

[10] Molecular, biochemical, and cellular pharmacology of pemetrexed [J].

Goldman, ID ;

Zhao, RB .

SEMINARS IN ONCOLOGY, 2002, 29 (06) :3-17

← 1 2 3 →